Strs Ohio Cuts Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Strs Ohio lessened its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 61,900 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. Strs Ohio’s holdings in Dynavax Technologies were worth $865,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BluePath Capital Management LLC acquired a new stake in Dynavax Technologies in the third quarter valued at about $33,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dynavax Technologies in the 3rd quarter valued at approximately $33,000. Advisor Resource Council purchased a new stake in shares of Dynavax Technologies in the fourth quarter valued at approximately $144,000. Rathbones Group PLC acquired a new position in Dynavax Technologies during the third quarter worth $158,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Dynavax Technologies in the fourth quarter worth $209,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $11.42 on Thursday. The firm has a market capitalization of $1.49 billion, a PE ratio of -190.30 and a beta of 1.26. Dynavax Technologies Co. has a 52 week low of $10.06 and a 52 week high of $15.15. The firm’s 50-day simple moving average is $12.28 and its 200 day simple moving average is $13.23. The company has a quick ratio of 12.96, a current ratio of 13.81 and a debt-to-equity ratio of 0.41.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price target for the company. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Insiders Place Their Bets

In other news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.98% of the stock is currently owned by company insiders.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.